TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review in Nutrients examined research on ergothioneine, an antioxidant found in mushrooms and other foods, and its possible effects on brain health. Some observational studies link lower blood levels with poorer cognition, but they cannot show cause and effect, and human trials have not established that ergothioneine prevents neurodegenerative disease.
Researchers from the University of Rzeszow reviewed evidence on whether ergothioneine, an antioxidant found in mushrooms and other foods, could help protect the aging brain. The review, published in Nutrients, summarizes observational studies linking blood ergothioneine levels with cognition, as well as laboratory and animal research. The authors note that these findings do not establish that eating mushrooms or taking ergothioneine prevents dementia.
The Nutrients review brings together studies of ergothioneine, often abbreviated ET, and neurodegenerative conditions including Alzheimer’s and Parkinson’s disease. The authors cite observational research that linked lower circulating ET with mild cognitive impairment, poorer cognitive performance, and faster declines in several cognitive and functional measures. Among the studies they discuss, a longitudinal study followed 470 people who had no cognitive impairment at the start; lower ET levels were associated with faster decline in global cognition, attention, memory, locomotion, and language.
The review authors caution that these findings show an association, not that low ET caused the changes. They suggest reduced levels might instead reflect greater antioxidant use during oxidative stress. The review also describes conflicting evidence: one study it cites associated higher serum ET with increased Alzheimer’s risk. In cell and animal experiments reviewed by the authors, ET administration reduced oxidative stress or improved outcomes, but some experiments used concentrations or doses higher than people would typically obtain from food.
The authors characterize evidence from people as limited and mixed. The review reports short trials that found changes in measures such as subjective sleep quality or memory, but says these do not show that ET prevents a neurodegenerative disease. It also discusses a 12-week trial of mushroom extract tablets that reported improved verbal memory in healthy participants and people with suspected mild cognitive impairment. Because the extract contained other mushroom compounds, the review notes that the result cannot be attributed to ET alone.
What the Findings Mean for Diet
The review adds to research on whether diet-related compounds might be connected to brain health, but it does not provide evidence that people can prevent dementia by eating more mushrooms. The authors distinguish associations in blood measurements from proof that increasing intake changes someone’s risk, and note that findings from cells or animals do not establish a benefit in people.
For readers, the findings are a reason to treat ET as a research question rather than a proven dietary intervention. The review discusses possible antioxidant and anti-inflammatory effects, including activity involving the body’s own antioxidant-response pathways. But its discussion of biological mechanisms does not establish that those processes translate into a meaningful, lasting clinical benefit.
The review notes that neurodegenerative diseases affect health, independence, and quality of life, and that no cure currently exists. Research into prevention may be valuable, but describing a compound as promising is not the same as showing it can prevent disease or replace established medical care.
Products Worth Considering
Philips Sonicare 6500 Series Rechargeable Electric Toothbrush with 2 Brush Heads, White
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
As an affiliate, we earn on qualifying purchases.
How Ergothioneine Was Studied
The review describes ergothioneine as a naturally occurring sulfur-containing antioxidant present in mushrooms and other foods. Researchers have examined it because oxidative stress accompanies neurodegenerative diseases and may contribute to damage, although the relationship is complex. The authors note that earlier research proposed inadequate dietary ET as a possible contributor to neurodegeneration, but say that hypothesis remains unproven.
The review summarizes evidence from research types that answer different questions. Observational studies compare ET levels with health or cognitive outcomes, while laboratory experiments and animal studies test possible effects under controlled conditions. Human trials have examined supplementation over weeks. One trial cited in the review tested 20 milligrams per day for four weeks among people reporting sleep difficulties and anxiety. Results from one setting cannot automatically be applied to another, and short trials cannot establish long-term disease prevention.
What Human Studies Cannot Yet Show
The review does not establish whether low ET levels contribute to cognitive decline, result from disease-related processes, or reflect other factors. Its authors also discuss a conflicting observation linking higher ET with Alzheimer’s risk, which cautions against treating blood levels as a straightforward indicator of protection.
As the review explains, it remains unclear whether eating more mushrooms raises ET levels enough to affect brain outcomes, what intake would be needed, or whether any effect would be specific to ET rather than other compounds in mushrooms. The human supplementation studies it describes were limited in duration and scope. Some reported subjective or temporary improvements, while a study of inflammatory and oxidative-damage biomarkers found downward trends that were not statistically significant. The review therefore does not show that ET prevents Alzheimer’s, Parkinson’s, or other neurodegenerative diseases.
Evidence Needed From Longer Trials
The review highlights the need for more research that can distinguish correlation from cause and test whether ET supplementation produces sustained benefits in people. Longer and larger human trials would need to measure clinically meaningful cognitive outcomes and follow participants for enough time to assess disease risk, rather than relying only on short-term biomarkers or self-reported changes.
As the review’s findings indicate, studies would also need to clarify dose, safety, and whether effects come from ET itself or from other ingredients in mushroom extracts. Until such evidence is available, the review supports further investigation, not a dietary prescription or a claim that mushrooms protect the brain against aging.
Key Questions
Does this review show that mushrooms prevent dementia?
No. The review discusses possible links and early findings, but it does not establish that eating mushrooms prevents dementia or other neurodegenerative diseases.
What is ergothioneine?
Ergothioneine is a naturally occurring antioxidant found in mushrooms and other foods. Researchers are studying its possible effects on oxidative stress, inflammation, and brain health.
Do lower blood levels mean someone will develop Alzheimer’s?
No. Observational studies cited in the review reported associations between lower ET levels and cognitive outcomes, but they cannot show that low levels cause disease or predict an individual’s future health.
Did human trials find a benefit?
The review describes some short trials that reported changes in sleep or memory measures, but the results were limited and do not demonstrate disease prevention. In one mushroom-extract trial, other compounds could have contributed to the reported memory changes.
Source: news-medical.net
